Azithromycin paradox in the treatment of cystic fibrosis airway disease

Future Microbiology

Volumn 5, Issue 9, 2010, Pages 1315-1319

  Sibley, Christopher D ^a   Grinwis, Margot E ^a   Rabin, Harvey R ^a   Surette, Michael G ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

cystic fbrosis; macrolide antibiotics

Indexed keywords

AZITHROMYCIN; PLACEBO;

ADOLESCENT; ADULT; BACTERIAL COLONIZATION; BODY MASS; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FIBROSIS; LUNG FUNCTION; MULTICENTER STUDY; NOTE; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPIROMETRY;

PSEUDOMONAS AERUGINOSA;

EID: 77957586291     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.99     Document Type: Note

References (52)

1. Saiman L, Anstead M, Mayer-Hamblett N et al.: Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 303(17), 1707-1715 (2010).
2. Saiman L, Marshall BC, Mayer-Hamblett N et al.: Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 290(13), 1749-1756 (2003).
3. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J: Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 57(3), 212-216 (2002).
4. Clement A, Tamalet A, Leroux E, Ravilly S, Fauroux B, Jais J: Long term effects of azithromycin in patients with cystic fibrosis: a double blind, placebo controlled trial. Thorax 61(10), 895-902 (2006).
5. Tramper-Stranders GA, Wolfs TFW, Fleer A, Kimpen JLL, van der Ent CK: Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function. Pediatr. Infect. Dis. J. 26(1), 8-12 (2007).
6. Florescu DF, Murphy PJ, Kalil AC: Effects of prolonged use of azithromycin in patients with cystic fibrosis: a meta-analysis. Pulm. Pharmacol. her. 22(6), 467-472 (2009).
7. Main E, Prasad A, Schans C: Conventional chest physiotherapy compared to other airway clearance techniques for cystic fibrosis. Cochrane Database Syst. Rev. (1), CD002011 (2005).
8. Fuchs HJ, Borowitz DS, Christiansen DH et al.: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N. Engl. J. Med. 331(10), 637-642 (1994).
9. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC: Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N. Engl. J. Med. 354(3), 241-250 (2006).
10. Koyama H, Geddes DM: Erythromycin and diffuse panbronchiolitis. Thorax 52(10), 915-918 (1997).
11. Tateda K, Ishii Y, Matsumoto T et al.: Direct evidence for antipseudomonal activity of macrolides: exposure-dependent bactericidal activity and inhibition of protein synthesis by erythromycin, clarithromycin, and azithromycin. Antimicrob. Agents Chemother. 40(10), 2271-2275 (1996).
12. Imamura Y, Higashiyama Y, Tomono K et al.: Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane. Antimicrob. Agents Chemother. 49(4), 1377-1380 (2005).
13. Baumann U, King M, App EM et al.: Long term azithromycin therapy in cystic fibrosis patients: a study on drug levels and sputum properties. Can. Respir. J. 11(2), 151-155 (2004).
14. Giamarellos-Bourboulis EJ: Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int. J. Antimicrob. Agents 31(1), 12-20 (2008).
15. Saiman L, Chen Y, Gabriel PS, Knirsch C: Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob. Agents Chemother. 46(4), 1105-1107 (2002).
16. Howe RA, Spencer RC: Macrolides for the treatment of Pseudomonas aeruginosa infections? J. Antimicrob. Chemother. 40(2), 153-155 (1997).
17. Kawamura-Sato K, Iinuma Y, Hasegawa T, Horii T, Yamashino T, Ohta M: Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob. Agents Chemother. 44(10), 2869-2872 (2000).
18. Hirakata Y, Kaku M, Mizukane R et al.: Potential effects of erythromycin on host defense systems and virulence of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 36(9), 1922-1927 (1992).
19. Kita E, Sawaki M, Oku D et al.: Suppression of virulence factors of Pseudomonas aeruginosa by erythromycin. J. Antimicrob. Chemother. 27(3), 273-284 (1991).
20. Mizukane R, Hirakata Y, Kaku M et al.: Comparative in vitro exoenzyme-suppressing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa . Antimicrob. Agents Chemother. 38(3), 528-533 (1994).
21. Molinari G, Guzmán CA, Pesce A, Schito GC: Inhibition of Pseudomonas aeruginosa virulence factors by subinhibitory concentrations of azithromycin and other macrolide antibiotics. J. Antimicrob. Chemother. 31(5), 681-688 (1993).
22. Wagner T, Soong G, Sokol S, Saiman L, Prince A: Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. Chest 128(2), 912-919 (2005).
23. Nagino K, Kobayashi H: Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin. Microbiol. Infect. 3(4), 432-439 (1997).
24. Ichimiya T, Takeoka K, Hiramatsu K, Hirai K, Yamasaki T, Nasu M: The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro. Chemotherapy 42(3), 186-191 (1996).
25. Yasuda H, Ajiki Y, Koga T, Kawada H, Yokota T: Interaction between biofilms formed by Pseudomonas aeruginosa and clarithromycin. Antimicrob. Agents Chemother. 37(9), 1749-1755 (1993).
26. Ichimiya T, Yamasaki T, Nasu M: In-vitro effects of antimicrobial agents on Pseudomonas aeruginosa biofilm formation. J. Antimicrob. Chemother. 34(3), 331-341 (1994).
27. Kobayashi H: Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am. J. Med. 99(6A), S26-S30 (1995).
28. Tamaoki J: The effects of macrolides on inflammatory cells. Chest 125(2 Suppl.), S41-S50 (2004).
29. Tsai WC, Rodriguez ML, Young KS et al.: Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am. J. Respir. Crit. Care Med. 170(12), 1331-1339 (2004).
30. Takizawa H, Desaki M, Ohtoshi T et al.: Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. Am. J. Respir. Crit. Care Med.156(1), 266-271 (1997). (Pubitemid 27293200)
31. Khan AA, Slifer TR, Araujo FG, Remington JS: Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int. J. Antimicrob. Agents 11(2), 121-132 (1999).
32. Abe S, Nakamura H, Inoue S et al.: Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. Am. J. Respir. Cell Mol. Biol. 22(1), 51-60 (2000).
33. Morikawa K, Watabe H, Araake M, Morikawa S: Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother. 40(6), 1366-1370 (1996).
34. Gant TW, OConnor CK, Corbitt R, Thorgeirsson U, Thorgeirsson SS: In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. 133(2), 269-276 (1995).
35. Jaffé A, Francis J, Rosenthal M, Bush A: Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 351(9100), 420 (1998).
36. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M: Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 360(9338), 978-984 (2002).
37. Ramsey BW, Pepe MS, Quan JM et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. cystic fibrosis inhaled tobramycin study group. N. Engl. J. Med. 340(1), 23-30 (1999).
38. Saiman L, Mayer-Hamblett N, Campbell P, Marshall BC, Group MS: Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 172(8), 1008-1012 (2005). (Pubitemid 41476538)
39. Equi AC, Davies JC, Painter H et al.: Exploring the mechanisms of macrolides in cystic fibrosis. Respir. Med. 100(4), 687-697 (2006).
40. Sibley CD, Rabin H, Surette MG: Cystic fibrosis: a polymicrobial infectious disease. Future Microbiol. 1(1), 53-61 (2006).
41. Duan K, Dammel C, Stein J, Rabin H, Surette MG: Modulation of Pseudomonas aeruginosa gene expression by host microflora through interspecies communication. Mol. Microbiol. 50(5), 1477-1491 (2003).
42. Sibley CD, Duan K, Fischer C et al.: Discerning the complexity of community interactions using a Drosophila model of polymicrobial infections. PLoS Pathog. 4(10), e1000184 (2008).
43. Sibley CD, Parkins MD, Rabin HR, Duan K, Norgaard JC, Surette MG: A polymicrobial perspective of pulmonary infections exposes an enigmatic pathogen in cystic fibrosis patients. Proc. Natl Acad. Sci. USA 105(39), 15070-15075 (2008).
44. Ergin A, Ercis S, Celik GH: Macrolide resistance mechanisms and in vitro susceptibility patterns of viridans group streptococci isolated from blood cultures. J. Antimicrob. Chemother. 57(1), 139-141 (2006).
45. Gordon KA, Beach ML, Biedenbach DJ, Jones RN, Rhomberg PR, Mutnick AH: Antimicrobial susceptibility patterns of beta-hemolytic and viridans group streptococci: report from the SENTRY antimicrobial surveillance program (1997-2000). Diagn. Microbiol. Infect. Dis. 43(2), 157-162 (2002).
46. Asmah N, Eberspächer B, Regnath T, Arvand M: Prevalence of erythromycin and clindamycin resistance among clinical isolates of the Streptococcus anginosus group in Germany. J. Med. Microbiol. 58 (Pt 2), 222-227 (2009).
47. Seppälä H, Haanperä M, Al-Juhaish M, Järvinen H, Jalava J, Huovinen P: Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from normal flora. J. Antimicrob. Chemother. 52(4), 636-644 (2003).
48. Malhotra-Kumar S, Lammens C, Martel A et al.: Oropharyngeal carriage of macrolide-resistant viridans group streptococci: a prevalence study among healthy adults in Belgium. J. Antimicrob. Chemother. 53(2), 271-276 (2004).
49. Aracil B, Minambres M, Oteo J, Torres C, Gómez-Garcés JL, Alós JI: High prevalence of erythromycin-resistant and clindamycin-susceptible (M phenotype) viridans group streptococci from pharyngeal samples: a reservoir of mef genes in commensal bacteria. J. Antimicrob. Chemother. 48(4), 592-594 (2001).
50. Eisenblätter M, Klaus C, Pletz MWR et al.: Influence of azithromycin and clarithromycin on macrolide susceptibility of viridans streptococci from the oral cavity of healthy volunteers. Eur. J. Clin. Microbiol. Infect. Dis. 27(11), 1087-1092 (2008).
51. Tazumi A, Maeda Y, Goldsmith CE et al.: Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J. Antimicrob. Chemother. 64(3), 501-506 (2009).
52. Grinwis ME, Sibley CD, Parkins MD, Eshaghurshan CS, Rabin HR, Surette MG: Macrolide and clindamycin resistance in Streptococcus milleri group isolates from cystic fibrosis airways. Antimicrob. Agents Chemother. 54(7), 2823-2829 (2010).